Skip to main content

Advertisement

SpringerLink
Log in

Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis

  • Spondyloarthritis (M Khan, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of review

We review the pathways, cytokines, and concepts important to the pathogenesis of bone resorption and formation in rheumatoid arthritis (RA) and spondyloarthritis (SpA).

Recent findings

Research in bone biology has shed light on the pathogenesis of the joint destruction that occurs in RA and in peripheral SpA. However, understanding the mechanisms behind the bone formation seen in peripheral and axial SpA has been challenging. Mouse models have been used to gain an understanding of key signaling pathways, cytokines and cells regulating inflammation in these diseases. Biologic therapies directed against these targets have been developed to control both inflammation and effects on bone.

Summary

Although biologic therapies improve joint inflammation in both RA and SpA, leading to a decrease in pain and improving quality of life for patients, the long-term effects of such therapies must also be evaluated by assessing their impact on structural progression. Inhibition of radiographic progression in both RA and peripheral SpA has been easier to demonstrate than in axial SpA. Here, we discuss the similarities and differences among biologic therapies as they pertain to radiographic progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Baum R, Gravallese EM. Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts. Clin Rev Allergy Immunol. 2015. doi:10.1007/s12016-015-8515-6.

    Google Scholar 

  2. •Gravallese EM, Goldering S, Schett G. Role of the immune system in the local and systemic bone loss in inflammatory arthritis. In: Osteoimmunology. Second ed. Elsevier; 2014. A comprehensive review of the role of cytokines, osteoblasts and osteoclasts, and their effects on bone in inflammatory arthritis.

  3. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43(2):250–8. doi:10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P.

    Article  CAS  PubMed  Google Scholar 

  4. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford). 2001;40(6):623–30.

    Article  CAS  Google Scholar 

  5. Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689–99. doi:10.1016/S0002-9440(10)63016-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110(10):1419–27. doi:10.1172/JCI15582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, et al. Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum. 2008;59(7):911–20. doi:10.1002/art.23818.

    Article  CAS  PubMed  Google Scholar 

  8. Lerner UH, Ohlsson C. The WNT system: background and its role in bone. J Intern Med. 2015;277(6):630–49. doi:10.1111/joim.12368.

    Article  CAS  PubMed  Google Scholar 

  9. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24(9):1572–85. doi:10.1359/jbmr.090320.

    Article  CAS  PubMed  Google Scholar 

  10. Matzelle MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS, et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 2012;64(5):1540–50. doi:10.1002/art.33504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63. doi:10.1038/nm1538.

    Article  CAS  PubMed  Google Scholar 

  12. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152–9. doi:10.1136/ard.2010.132852.

    Article  CAS  PubMed  Google Scholar 

  13. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38(5):821–7. doi:10.3899/jrheum.100089.

    Article  CAS  PubMed  Google Scholar 

  14. Yeremenko N, Zwerina K, Rigter G, Pots D, Fonseca JE, Zwerina J, et al. Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol. 2015;67(8):2071–5. doi:10.1002/art.39183.

    Article  CAS  PubMed  Google Scholar 

  15. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403–40. doi:10.1210/er.2007-0038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 2002;277(4):2695–701. doi:10.1074/jbc.M106339200.

    Article  CAS  PubMed  Google Scholar 

  17. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002;46(3):785–92. doi:10.1002/art.10097.

    Article  CAS  PubMed  Google Scholar 

  18. Shaw AT, Gravallese EM. Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol. 2016;49:2–10. doi:10.1016/j.semcdb.2015.10.013.

    Article  CAS  PubMed  Google Scholar 

  19. Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF-α on Bone Homeostasis. Front Immunol. 2014;5:48. doi:10.3389/fimmu.2014.00048.

    PubMed  PubMed Central  Google Scholar 

  20. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988;18(11):1797–801. doi:10.1002/eji.1830181122.

    Article  CAS  PubMed  Google Scholar 

  21. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247–56. doi:10.1177/1759720X10378372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146(4):1991–8. doi:10.1210/en.2004-1167.

    Article  CAS  PubMed  Google Scholar 

  23. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003;171(6):3202–9.

    Article  CAS  PubMed  Google Scholar 

  24. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998;95(14):8222–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187(4):461–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O. Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem. 2004;91(5):1053–61. doi:10.1002/jcb.20004.

    Article  CAS  PubMed  Google Scholar 

  27. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345–52. doi:10.1172/JCI5703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhang F, Tanaka H, Kawato T, Kitami S, Nakai K, Motohashi M, et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie. 2011;93(2):296–305. doi:10.1016/j.biochi.2010.10.001.

    Article  CAS  PubMed  Google Scholar 

  29. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 2000;164(5):2832–8.

    Article  CAS  PubMed  Google Scholar 

  30. ••Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(10):562. doi:10.1038/nrrheum.2015.128. Review of current basic research on the IL-23/IL-17 axis and its importance in the pathogenesis of both SpA and RA. This article also presents the hypothesis that IL-17/IL-23 inhibition might more likely be effective in early, rather than established, RA.

    Article  PubMed  Google Scholar 

  31. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 2010;37(10):2014–20. doi:10.3899/jrheum.100259.

    Article  CAS  PubMed  Google Scholar 

  32. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198(12):1951–7. doi:10.1084/jem.20030896.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ratsimandresy RA, Duvallet E, Assier E, Semerano L, Delavallée L, Bessis N, et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine. 2011;29(50):9329–36. doi:10.1016/j.vaccine.2011.09.134.

    Article  CAS  PubMed  Google Scholar 

  34. Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E. IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis. PLoS ONE. 2013;8(2), e57553. doi:10.1371/journal.pone.0057553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S, et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol. 2008;181(8):5720–9.

    Article  CAS  PubMed  Google Scholar 

  36. Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY, et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol. 2008;181(2):1507–18.

    Article  CAS  PubMed  Google Scholar 

  37. Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum. 2010;62(4):1043–50. doi:10.1002/art.27336.

    Article  CAS  PubMed  Google Scholar 

  38. ••Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76. doi:10.1038/nm.2817. This study established a role for IL-23 in the pathogenesis of SpA and identified a unique T cell expressing the IL-23R at enthesial sites.

    Article  CAS  PubMed  Google Scholar 

  39. Krausz S, Boumans MJ, Gerlag DM, Lufkin J, van Kuijk AW, Bakker A, et al. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1750–5. doi:10.1002/art.34339.

    Article  CAS  PubMed  Google Scholar 

  40. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352(9134):1137–40. doi:10.1016/S0140-6736(97)12004-9.

    Article  CAS  PubMed  Google Scholar 

  41. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482–91. doi:10.1002/art.22758.

    Article  PubMed  Google Scholar 

  42. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572–4. doi:10.1136/annrheumdis-2011-200216.

    Article  CAS  PubMed  Google Scholar 

  43. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60(11):3257–62. doi:10.1002/art.24888.

    Article  PubMed  Google Scholar 

  44. •Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ, et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013;72(10):1732–6. doi:10.1136/annrheumdis-2013-203345. These data support the use of anti-sclerostin antibodies to treat bone loss in inflammatory arthritis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. ••Wehmeyer C, Frank S, Beckmann D, Böttcher M, Cromme C, König U, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330):330ra35. doi:10.1126/scitranslmed.aac4351. This demonstrates that inflammation worsens after administration of an anti-sclerostin antibody in TNF-driven animal models of arthritis and raises questions as to the role of sclerostin inhibition in inflammatory arthritis.

    Article  PubMed  Google Scholar 

  46. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269–73. doi:10.1007/s10067-010-1647-4.

    Article  PubMed  Google Scholar 

  47. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9. doi:10.1136/annrheumdis-2013-204655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9. doi:10.1016/S0140-6736(13)60594-2.

    Article  CAS  PubMed  Google Scholar 

  49. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.1136/annrheumdis-2013-204248.

    Article  CAS  PubMed  Google Scholar 

  50. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3. doi:10.1126/science.1135245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol. 2009;36(1):137–40. doi:10.3899/jrheum.080458.

    CAS  PubMed  Google Scholar 

  52. Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev. 2010;233(1):181–202. doi:10.1111/j.0105-2896.2009.00865.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Goodall JC, Wu C, Zhang Y, McNeill L, Ellis L, Saudek V, et al. Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A. 2010;107(41):17698–703. doi:10.1073/pnas.1011736107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314–24. doi:10.1038/ni.1698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76. doi:10.1016/j.immuni.2004.08.018.

    Article  CAS  PubMed  Google Scholar 

  56. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307–17. doi:10.1002/art.23655.

    Article  PubMed  Google Scholar 

  57. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31(2):331–41. doi:10.1016/j.immuni.2009.08.001.

    Article  CAS  PubMed  Google Scholar 

  58. •Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing γδ T cells enhance bone regeneration. Nat Commun. 2016;7:10928. doi:10.1038/ncomms10928. Study highlighting the role of IL-17 in bone homeostasis, showing that IL-17 promotes osteoblast mesenchymal progenitor cell differentiation in a mouse model of bone fracture repair.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. •Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med. 2016;8(330):330ra37. doi:10.1126/scitranslmed.aad899. Study highlighting the complex function of IL-17 in bone homeostasis and demonstrating that IL-17A inhibits osteoblast differentiation and promotes systemic bone loss.

    Article  PubMed  Google Scholar 

  60. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46. doi:10.1016/S0140-6736(15)61134-5.

    Article  CAS  PubMed  Google Scholar 

  61. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015;373(14):1329–39. doi:10.1056/NEJMoa1412679.

    Article  CAS  PubMed  Google Scholar 

  62. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066.

    Article  CAS  PubMed  Google Scholar 

  63. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis. 2005;64(11):1557–62. doi:10.1136/ard.2004.035105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. doi:10.1002/art.21913.

    Article  PubMed  CAS  Google Scholar 

  65. Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12. doi:10.1002/art.23969.

    Article  CAS  PubMed  Google Scholar 

  66. Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol. 2015;67(3):668–77. doi:10.1002/art.38973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–93.

    Article  CAS  PubMed  Google Scholar 

  68. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091–102. doi:10.1002/art.38721.

    Article  CAS  PubMed  Google Scholar 

  69. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702–12. doi:10.1002/art.39257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815–22. doi:10.1136/annrheumdis-2012-201766.

    Article  CAS  PubMed  Google Scholar 

  71. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39–47. doi:10.1136/annrheumdis-2013-204231.

    Article  PubMed  CAS  Google Scholar 

  72. Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):155–61. doi:10.1016/j.semarthrit.2014.05.008.

    Article  PubMed  CAS  Google Scholar 

  73. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009;60(1):93–102. doi:10.1002/art.24132.

    Article  PubMed  Google Scholar 

  74. Pedersen SJ, Chiowchanwisawakit P, Lambert RG, Østergaard M, Maksymowych WP. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol. 2011;38(7):1349–54. doi:10.3899/jrheum.100925.

    Article  CAS  PubMed  Google Scholar 

  75. Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73(10):1819–25. doi:10.1136/annrheumdis-2013-203425.

    Article  CAS  PubMed  Google Scholar 

  76. •Maksymowych WP. Evidence in support of the validity of the TNF brake hypothesis. Ann Rheum Dis. 2013;72(12):e31. doi:10.1136/annrheumdis-2013-204485. Opinion piece on the “TNF brake hypothesis”.

    Article  PubMed  Google Scholar 

  77. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54. doi:10.1002/art.38070.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86(16):6367–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24(3):518–23.

    CAS  PubMed  Google Scholar 

  80. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65(12):1551–7. doi:10.1136/ard.2005.050963.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Alenius GM, Eriksson C, Rantapää DS. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol. 2009;27(1):120–3.

    PubMed  Google Scholar 

  82. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010;36(2):385–404. doi:10.1016/j.rdc.2010.03.003.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Braun J. et al. Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol EULAR; 2015; Rome, Italy. Oral presentation: OP0171.

  84. Baraliakos X, editor. Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab. ACR/ARHP Annual Meeting; 2015; San Francisco, California.

  85. Thorne C. et al. Response and Radiographic Progression in Biologic-naive and Biologic-experienced Patients with Rheumatoid Arthritis Treated with Sirukumab. EULAR; 2016; London, UK; Abstract # SAT0158.

  86. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863–7. doi:10.1136/ard.2008.091793.

    Article  PubMed  Google Scholar 

  87. Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004;50(8):2622–32. doi:10.1002/art.20446.

    Article  PubMed  Google Scholar 

  88. Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127–9. doi:10.1136/ard.2004.020503.

    Article  CAS  PubMed  Google Scholar 

  89. Althoff CE, Sieper J, Song IH, Haibel H, Weiß A, Diekhoff T, et al. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis. 2013;72(6):967–73. doi:10.1136/annrheumdis-2012-201545.

    Article  PubMed  Google Scholar 

  90. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261–3.

    PubMed  Google Scholar 

  91. Østergaard M, Edmonds J, McQueen F, Peterfy C, Lassere M, Ejbjerg B, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis. 2005;64 Suppl 1:i3–7. doi:10.1136/ard.2004.031773.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–11. doi:10.1002/art.20217.

    Article  CAS  PubMed  Google Scholar 

  93. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594–602. doi:10.1056/NEJM200011303432202.

    Article  CAS  PubMed  Google Scholar 

  94. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–81. doi:10.1016/S0140-6736(04)15640-7.

    Article  CAS  PubMed  Google Scholar 

  95. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200–10. doi:10.1002/art.30263.

    Article  CAS  PubMed  Google Scholar 

  96. Keystone E, Heijde D, Mason D, Landewé R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319–29. doi:10.1002/art.23964.

    Article  CAS  PubMed  Google Scholar 

  97. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797–804. doi:10.1136/ard.2008.101659.

    Article  CAS  PubMed  Google Scholar 

  98. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–43. doi:10.1136/ard.2005.045658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712–21.

    CAS  PubMed  Google Scholar 

  100. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476–88. doi:10.1002/art.22379.

    Article  CAS  PubMed  Google Scholar 

  101. van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73(1):233–7. doi:10.1136/annrheumdis-2013-203697.

    Article  PubMed  CAS  Google Scholar 

  102. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–17. doi:10.1002/art.34436.

    Article  CAS  PubMed  Google Scholar 

  103. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710–5. doi:10.1136/annrheumdis-2012-202698.

    Article  CAS  PubMed  Google Scholar 

  104. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23. doi:10.1136/ard.2008.092932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Baillet A, Gossec L, Paternotte S, Etcheto A, Combe B, Meyer O, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res (Hoboken). 2015;67(7):905–12. doi:10.1002/acr.22513.

    Article  CAS  Google Scholar 

  106. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–21. doi:10.1002/art.30158.

    Article  CAS  PubMed  Google Scholar 

  107. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–91. doi:10.1136/annrheumdis-2015-207628.

    Article  PubMed  Google Scholar 

  108. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015;67(6):1424–37. doi:10.1002/art.39093.

    Article  CAS  PubMed  Google Scholar 

  109. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95–100. doi:10.1136/annrheumdis-2013-203559.

    Article  CAS  PubMed  Google Scholar 

  110. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–7. doi:10.1136/annrheumdis-2013-204963.

    Article  PubMed  Google Scholar 

  111. Mease P, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase 2b Study of Adults with Active Psoriatic Arthritis. Arthritis Rheumatol. 2016. doi:10.1002/art.39700.

    PubMed Central  Google Scholar 

  112. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72(6):863–9. doi:10.1136/annrheumdis-2012-201601.

    Article  CAS  PubMed  Google Scholar 

  113. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41(3):414–21. doi:10.3899/jrheum.130637.

    Article  CAS  PubMed  Google Scholar 

  114. Tlustochowicz W, Rahman P, Seriolo B, Krammer G, Porter B, Widmer A, et al. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. J Rheumatol. 2016;43(3):495–503. doi:10.3899/jrheum.150117. Study of IL-17 inhibition in RA patients inadequately responsive to treatment with methotrexate.

    Article  PubMed  Google Scholar 

  115. Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, et al. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. J Rheumatol. 2016;43(2):289–97. doi:10.3899/jrheum.140831. Study of treatment with another IL-17 inhibitor in RA patients.

    Article  CAS  PubMed  Google Scholar 

  116. Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015;42(6):912–9. doi:10.3899/jrheum.141271.

    Article  CAS  PubMed  Google Scholar 

  117. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71(10):1741–8. doi:10.1136/annrheumdis-2011-201024.

    Article  CAS  PubMed  Google Scholar 

  118. •Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, et al. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 2015;67(1):51–62. doi:10.1002/art.38896. Study supporting the hypothesis that combined inhibition of TNF and IL-17 may be more effective than IL-17 inhibition alone.

    Article  CAS  PubMed  Google Scholar 

  119. van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, et al. Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis Rheumatol. 2016. doi:10.1002/art.39685.

    Google Scholar 

  120. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–306. doi:10.1056/NEJMoa1315231.

    Article  PubMed  CAS  Google Scholar 

  121. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2016-209709.

    Google Scholar 

  122. Shaw AT, Maeda Y, Gravallese EM. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther. 2016;18(1):104. doi:10.1186/s13075-016-0998-x.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells. Front Immunol. 2014;5:425. doi:10.3389/fimmu.2014.00425.

    PubMed  PubMed Central  Google Scholar 

  124. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–6. doi:10.1136/annrheumdis-2013-204741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken). 2015;67(12):1739–49. doi:10.1002/acr.22645.

    Article  CAS  Google Scholar 

  126. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806. doi:10.1002/art.22025.

    Article  CAS  PubMed  Google Scholar 

  127. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216–21. doi:10.1136/ard.2007.085787.

    Article  CAS  PubMed  Google Scholar 

  128. Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69(6):1158–61. doi:10.1136/ard.2009.119222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71(3):351–7. doi:10.1136/annrheumdis-2011-200170.

    Article  CAS  PubMed  Google Scholar 

  130. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62(5):1290–7. doi:10.1002/art.27383.

    Article  CAS  PubMed  Google Scholar 

  131. Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol. 2012;39(12):2327–31. doi:10.3899/jrheum.120201.

    Article  CAS  PubMed  Google Scholar 

  132. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70(6):1108–10. doi:10.1136/ard.2010.145946.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, 55 Lake Ave North, Worcester, MA, 01655, USA

    Zheni Stavre, Katherine Upchurch, Jonathan Kay & Ellen M. Gravallese

  2. University of Massachusetts Medical School, Lazar Research Building, 364 Plantation Street, Worcester, MA, 01605, USA

    Zheni Stavre, Katherine Upchurch, Jonathan Kay & Ellen M. Gravallese

Authors
  1. Zheni Stavre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine Upchurch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan Kay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ellen M. Gravallese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellen M. Gravallese.

Ethics declarations

Conflicts of Interest

EG reports grants from AbbVie Inc, personal fees from AbbVie Inc, Eli Lilly and Company, GlaxoSmithKline PLC, Novartis Pharmaceuticals Corporation, Sanofi, and UpToDate.

JK reports grants and personal fees from AbbVie Inc, Genentech Inc, GlaxoSmithKline PLC, UCB Inc, Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, personal fees from Amgen, Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Crescendo Bioscience Inc, Epirus Biopharmaceuticals Inc, Hospira Inc, Janssen Biotech Inc, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc, Samsung Bioepis, Sandoz Inc, and UpToDate.

KU and ZS declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any primary studies with human or animal subjects performed by the authors.

Additional information

This article is part of the Topical Collection on Spondyloarthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stavre, Z., Upchurch, K., Kay, J. et al. Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Curr Rheumatol Rep 18, 72 (2016). https://doi.org/10.1007/s11926-016-0620-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0620-x

Keywords

Search

Navigation